vs
Side-by-side financial comparison of HIVE Digital Technologies Ltd. (HIVE) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
HIVE Digital Technologies Ltd. is the larger business by last-quarter revenue ($93.1M vs $86.8M, roughly 1.1× IOVANCE BIOTHERAPEUTICS, INC.). On growth, HIVE Digital Technologies Ltd. posted the faster year-over-year revenue change (218.6% vs 17.7%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 102.2%).
Mastech Digital, Inc. is a digital transformation and information technology (IT) services company headquartered in Pittsburgh, Pennsylvania, providing services to corporations across North America, Middle East, Asian, and Japan.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
HIVE vs IOVA — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $93.1M | $86.8M |
| Net Profit | $-91.3M | — |
| Gross Margin | -27.1% | 67.4% |
| Operating Margin | — | -84.7% |
| Net Margin | -98.1% | — |
| Revenue YoY | 218.6% | 17.7% |
| Net Profit YoY | -234.0% | — |
| EPS (diluted) | $-0.38 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $93.1M | $86.8M | ||
| Q3 25 | $87.3M | $67.5M | ||
| Q2 25 | $45.6M | $60.0M | ||
| Q1 25 | — | $49.3M | ||
| Q4 24 | $29.2M | $73.7M | ||
| Q3 24 | $22.6M | $58.6M | ||
| Q2 24 | $32.2M | $31.1M | ||
| Q1 24 | — | $715.0K |
| Q4 25 | $-91.3M | — | ||
| Q3 25 | $-15.8M | $-91.3M | ||
| Q2 25 | $35.0M | $-111.7M | ||
| Q1 25 | — | $-116.2M | ||
| Q4 24 | $68.2M | — | ||
| Q3 24 | $80.0K | $-83.5M | ||
| Q2 24 | $-18.3M | $-97.1M | ||
| Q1 24 | — | $-113.0M |
| Q4 25 | -27.1% | 67.4% | ||
| Q3 25 | 4.7% | 43.0% | ||
| Q2 25 | -13.6% | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | -43.7% | 68.7% | ||
| Q3 24 | -66.1% | 46.2% | ||
| Q2 24 | -7.4% | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | — | -84.7% | ||
| Q3 25 | — | -140.7% | ||
| Q2 25 | — | -189.8% | ||
| Q1 25 | — | -245.8% | ||
| Q4 24 | — | -117.5% | ||
| Q3 24 | — | -152.1% | ||
| Q2 24 | — | -327.6% | ||
| Q1 24 | — | -16464.6% |
| Q4 25 | -98.1% | — | ||
| Q3 25 | -18.1% | -135.3% | ||
| Q2 25 | 76.8% | -186.2% | ||
| Q1 25 | — | -235.5% | ||
| Q4 24 | 233.2% | — | ||
| Q3 24 | 0.4% | -142.7% | ||
| Q2 24 | -56.7% | -312.2% | ||
| Q1 24 | — | -15800.8% |
| Q4 25 | $-0.38 | — | ||
| Q3 25 | $-0.07 | — | ||
| Q2 25 | $0.18 | $-0.33 | ||
| Q1 25 | — | $-0.36 | ||
| Q4 24 | $0.52 | $-0.24 | ||
| Q3 24 | $0.00 | $-0.28 | ||
| Q2 24 | $-0.17 | $-0.34 | ||
| Q1 24 | — | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $559.3M | $698.6M |
| Total Assets | $624.0M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $297.0M | ||
| Q3 25 | — | $300.8M | ||
| Q2 25 | — | $301.2M | ||
| Q1 25 | — | $359.7M | ||
| Q4 24 | $40.5M | $323.8M | ||
| Q3 24 | $31.7M | $397.5M | ||
| Q2 24 | — | $412.5M | ||
| Q1 24 | — | $356.2M |
| Q4 25 | $559.3M | $698.6M | ||
| Q3 25 | $624.6M | $702.3M | ||
| Q2 25 | $560.5M | $698.5M | ||
| Q1 25 | — | $767.9M | ||
| Q4 24 | $430.9M | $710.4M | ||
| Q3 24 | $275.5M | $773.5M | ||
| Q2 24 | $268.6M | $768.5M | ||
| Q1 24 | — | $680.0M |
| Q4 25 | $624.0M | $913.2M | ||
| Q3 25 | $693.0M | $904.9M | ||
| Q2 25 | $628.7M | $907.4M | ||
| Q1 25 | — | $966.7M | ||
| Q4 24 | $478.6M | $910.4M | ||
| Q3 24 | $334.7M | $991.1M | ||
| Q2 24 | — | $964.3M | ||
| Q1 24 | — | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $46.0M | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $46.0M | $-52.6M | ||
| Q3 25 | $-10.6M | $-78.7M | ||
| Q2 25 | $10.2M | $-67.4M | ||
| Q1 25 | — | $-103.7M | ||
| Q4 24 | $-28.5M | $-73.3M | ||
| Q3 24 | $-2.2M | $-59.0M | ||
| Q2 24 | $-4.4M | $-98.4M | ||
| Q1 24 | — | $-122.3M |
| Q4 25 | — | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | $-55.5M | $-77.5M | ||
| Q3 24 | $-34.7M | $-61.3M | ||
| Q2 24 | — | $-98.9M | ||
| Q1 24 | — | $-126.5M |
| Q4 25 | — | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | -189.9% | -105.1% | ||
| Q3 24 | -153.4% | -104.6% | ||
| Q2 24 | — | -317.9% | ||
| Q1 24 | — | -17685.3% |
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | 92.5% | 5.7% | ||
| Q3 24 | 143.9% | 3.9% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 583.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.29× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.42× | — | ||
| Q3 24 | -26.94× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HIVE
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
